Bufalin Induces Mitochondria-Dependent Apoptosis in Pancreatic and Oral Cancer Cells by Downregulating hTERT Expression via Activation of the JNK/p38 Pathway

Evidence-based Complementary and Alternative Medicine : ECAM
Xin TianYouhong Jiang

Abstract

Bufalin, a digoxin-like active component of the traditional Chinese medicine Chan Su, exhibits potent antitumor activities in many human cancers. Bufalin induces mitochondria-dependent apoptosis in cancer cells, but the detailed molecular mechanisms are largely unknown. hTERT, the catalytic subunit of telomerase, protects against mitochondrial damage by binding to mitochondrial DNA and reducing mitochondrial ROS production. In the present study, we investigated the effects of bufalin on the cell viability, ROS production, DNA damage, and apoptosis of CAPAN-2 human pancreatic and CAL-27 human oral cancer cells. Bufalin reduced CAPAN-2 and CAL-27 cell viability with IC50 values of 159.2 nM and 122.6 nM, respectively. The reduced cell viability was accompanied by increased ROS production, DNA damage, and apoptosis and decreased expression of hTERT. hTERT silencing in CAPAN-2 and CAL-27 cells by siRNA resulted in increased caspase-9/-3 cleavage and DNA damage and decreased cell viability. Collectively, these data suggest that bufalin downregulates hTERT to induce mitochondria-dependent apoptosis in CAPAN-2 and CAL-27 cells. Moreover, bufalin increased the phosphorylation of JNK and p38-MAPK in CAPAN-2 and CAL-27 cells, and blocking...Continue Reading

References

Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Jun 11, 1998·Phytochemistry·L Krenn, B Kopp
Jul 20, 2002·Methods in Enzymology·Shazib Pervaiz, Marie-Véronique Clément
Sep 5, 2002·Microbiology and Molecular Biology Reviews : MMBR·Yu-Sheng CongJerry W Shay
Jun 25, 2008·Cell Research·Yusheng Cong, Jerry W Shay
Mar 7, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Judith HaendelerStefanie Dimmeler
Apr 4, 2009·Anti-cancer Drugs·Dan LiYunpeng Liu
Jul 14, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Lei SunXunbin Wei
Jan 5, 2013·Mutation Research·Evelyn LamyVolker Mersch-Sundermann
Jan 16, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Pei-Hao YinQi Li
Nov 13, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Meiying LiJisheng Li
Feb 27, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Dewei Wang, Zhenggang Bi
Mar 4, 2014·Journal of Translational Medicine·Zhou-Ji ZhangWei-Zhong Wu
May 23, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Xin TianJun Fang
Oct 3, 2014·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·Xian-Biao XieJing-Nan Shen
Jan 6, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Da-Wei DingXun Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
PCR
enzyme-linked immunosorbent assay
Transfection
flow cytometry
xenograft

Software Mentioned

GraphPad
NIS
Elements
Graphpad Prism

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2022 Meta ULC. All rights reserved